Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory read more 04/27/21
Castle Biosciences Announces Expanded Medicare Coverage for DecisionDx-Melanoma in Cutaneous Melanoma read more 10/08/20
PhaseBio Doses First Patients in Canada as Part of the REVERSE-IT Global Phase 3 Trial of Bentracimab read more 10/06/20
Mindera Corporation Announces Appointment of George W. Mahaffey as President and Chief Executive Officer read more 07/27/20
Castle Biosciences Announces Pricing of $74.0 Million Public Offering of Common Stock read more 06/24/20
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients read more 05/27/20
